Cargando…
The characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target
The inhibition of tumor angiogenesis is one of the main challenges in cancer therapy. With the aim of developing monoclonal antibodies able to inhibit angiogenesis, we immunized mice with proliferating human umbilical vein endothelial cells. We generated a library of monoclonal antibodies able to re...
Autores principales: | Orlandini, Maurizio, Galvagni, Federico, Bardelli, Monia, Rocchigiani, Marina, Lentucci, Claudia, Anselmi, Francesca, Zippo, Alessio, Bini, Luca, Oliviero, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058042/ https://www.ncbi.nlm.nih.gov/pubmed/24809468 |
Ejemplares similares
-
CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration
por: Galvagni, Federico, et al.
Publicado: (2016) -
CD93 Signaling via Rho Proteins Drives Cytoskeletal Remodeling in Spreading Endothelial Cells
por: Barbera, Stefano, et al.
Publicado: (2021) -
An apical actin-rich domain drives the establishment of cell polarity during cell adhesion
por: Galvagni, Federico, et al.
Publicado: (2012) -
The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization
por: Tosi, Gian Marco, et al.
Publicado: (2020) -
Bioinformatics Approaches to Predict Mutation Effects in the Binding Site of the Proangiogenic Molecule CD93
por: Cicaloni, Vittoria, et al.
Publicado: (2022)